The experts will assess unblinded data from BEACON-IPF to figure out why a data safety monitoring board recommended ...

Megakaryocytes form a three-dimensional (3D) cage composed of laminin and collagen IV connected to the basement membrane surrounding them. This microarchitecture stabilizes megakaryocytes within their ...

Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce ...

Pliant Therapeutics has pumped the breaks on a mid-stage trial of its lead liver disease drug on the advice of its safety ...

The company halted enrollment and dosing for its BEACON-IPF Phase 2b trial based on a recommendation from the DSMB.

Shares in Pliant Therapeutics plunged in after-hours trading after the US biotech revealed that it has paused a phase 2b/3 ...

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have been given an average rating of “Hold” by the eleven analysts that are presently covering the company, Marketbeat reports.

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Fintel reports that on February 10, 2025, Canaccord Genuity downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) ...

Fintel reports that on February 10, 2025, Citigroup downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from Buy ...

A substantial and persuasive body of data now exists that supports the view that integrin alpha V beta 3 plays a critical part in activated macrophage dependent inflammation, osteoclast development, ...